WO2011109726A3 - Anticorps homologues multispécifiques - Google Patents

Anticorps homologues multispécifiques Download PDF

Info

Publication number
WO2011109726A3
WO2011109726A3 PCT/US2011/027222 US2011027222W WO2011109726A3 WO 2011109726 A3 WO2011109726 A3 WO 2011109726A3 US 2011027222 W US2011027222 W US 2011027222W WO 2011109726 A3 WO2011109726 A3 WO 2011109726A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific antibodies
homologous
homologous multi
bind
relevant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/027222
Other languages
English (en)
Other versions
WO2011109726A2 (fr
WO2011109726A9 (fr
Inventor
Jay M. Short
Hwai Wen Chang
Gerhard Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of WO2011109726A2 publication Critical patent/WO2011109726A2/fr
Publication of WO2011109726A3 publication Critical patent/WO2011109726A3/fr
Publication of WO2011109726A9 publication Critical patent/WO2011109726A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne la production et l'optimisation d'anticorps homologues multispécifiques, des anticorps qui se distinguent par leur capacité à se lier à de multiples antigènes avec une spécificité et une affinité élevées. L'invention concerne également d'autres protéines multispécifiques qui se lient à plusieurs cibles.
PCT/US2011/027222 2010-03-05 2011-03-04 Anticorps homologues multispécifiques Ceased WO2011109726A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33953310P 2010-03-05 2010-03-05
US61/339,533 2010-03-05

Publications (3)

Publication Number Publication Date
WO2011109726A2 WO2011109726A2 (fr) 2011-09-09
WO2011109726A3 true WO2011109726A3 (fr) 2012-01-26
WO2011109726A9 WO2011109726A9 (fr) 2012-03-08

Family

ID=44542856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/027222 Ceased WO2011109726A2 (fr) 2010-03-05 2011-03-04 Anticorps homologues multispécifiques

Country Status (1)

Country Link
WO (1) WO2011109726A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2741175T3 (es) 2010-07-16 2020-02-10 Bioatla Llc Nuevos métodos de evolución de proteínas
AU2013259276B2 (en) * 2012-05-10 2018-03-22 Bioatla Llc Multi-specific monoclonal antibodies
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
DK4074735T3 (da) 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
PL3455261T3 (pl) 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
CN109475627B (zh) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
CA3055200A1 (fr) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions et methodes pour immunotherapie
WO2019241315A1 (fr) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie
WO2019241216A1 (fr) 2018-06-14 2019-12-19 Bioatla, Llc Constructions d'anticorps multi-spécifiques
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021046451A1 (fr) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions et méthodes de régulation de protéine accordable dhfr

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20070111260A1 (en) * 2005-10-14 2007-05-17 Medimmune, Inc. Cell display of antibody libraries
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
WO2011009058A2 (fr) * 2009-07-17 2011-01-20 Bioatla, Llc Sélection et évolution intégrées simultanées de la performance et de l’expression d’un anticorps/d’une protéine chez des hôtes de production

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20070111260A1 (en) * 2005-10-14 2007-05-17 Medimmune, Inc. Cell display of antibody libraries
WO2011009058A2 (fr) * 2009-07-17 2011-01-20 Bioatla, Llc Sélection et évolution intégrées simultanées de la performance et de l’expression d’un anticorps/d’une protéine chez des hôtes de production

Also Published As

Publication number Publication date
WO2011109726A2 (fr) 2011-09-09
WO2011109726A9 (fr) 2012-03-08

Similar Documents

Publication Publication Date Title
WO2011109726A3 (fr) Anticorps homologues multispécifiques
HK1210620A1 (en) Multi-specific monoclonal antibodies
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
MX340556B (es) Anticuerpos biespecificos activables.
WO2011056644A3 (fr) Anticorps anti-glp-1r et leurs utilisations
HK1207654A1 (en) Modified antibody regions and uses thereof
WO2012125733A3 (fr) Méthodes de dépistage d'anticorps
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
WO2011113019A3 (fr) Protéines ctla4 et leurs utilisations
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
WO2014150877A3 (fr) Anticorps anti-tau et leurs procédés d'utilisation
WO2011097301A3 (fr) Procédés et compositions de prédiction de la réponse à un traitement avec un inhibiteur du tnf-α
WO2013188693A8 (fr) Constructions de liaison à l'antigène pour cd3
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
WO2014189973A3 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
UA111818C2 (uk) Антитіло проти csf-1r
EA201201016A1 (ru) Антидоты антикоагулянтов
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
WO2014125374A3 (fr) Anticorps anti-tnf alpha hautement galactosylés et leurs utilisations
EA201291065A1 (ru) Антитела против vla-4
WO2014106015A3 (fr) Compositions protéiques à liaison multivalente
WO2012131555A3 (fr) Immunoglobulines hétéro-dimériques
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
WO2014078268A3 (fr) Anticorps anti-hémagglutinine et leurs procédés d'utilisation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11751433

Country of ref document: EP

Kind code of ref document: A2